Pharmaceutical Executive-07-01-2018

Pharmaceutical Executive

The role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).

Pharmaceutical Executive

Outlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”

Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.

Pharmaceutical Executive

While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.

Pharmaceutical Executive
From the Editor

July 09, 2018

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?

Pharmaceutical Executive
Columns

July 08, 2018

How navigating compliance risks requires so much more than policies and procedures.

Pharmaceutical Executive

Streamlined clinical research, more guidance speed new cures to patients.

Pharmaceutical Executive

Exploring the prospects-and related challenges-for Chinese life science as it aggressively pursues new growth areas.

Special Sponsored Section
Pharmaceutical Executive

July 01, 2018

The Indian pharmaceutical industry is traditionally known as a global powerhouse for the production of bulk drugs and generics, but less heralded is the growth India has made on the pharma world stage in several other areas, including biotechnology and R&D.

Issue PDF
Pharmaceutical Executive

July 01, 2018

Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.